XPO1 and central nervous system neoplasm: A phase I trial of the exportin-1 inhibitor selinexor for paediatric patients with recurrent/refractory solid and CNS tumours established the maximal tolerated dose and recommended a phase II (NCT05985161) starting dose of 35 mg/m2 for patients with recurrent/progressive ATRTs [85].